Trial Profile
A Randomized, Open-label (formerly Double-Blind), Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Lenvatinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eisai Co Ltd; Eisai Inc
- 08 Mar 2024 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 30 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Mar 2024.
- 31 Aug 2023 Planned End Date changed from 31 Aug 2023 to 31 Dec 2023.